A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) - Join Clinical Trial NCTNCT06504394
How to Join This Clinical Trial - NCTNCT06504394
Learn how to participate in this PHASE2 trial studying an investigational therapy for Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE2 - Safety and effectiveness study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT06504394 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 26 locations. Find a study site near you:
Clinical Research Site
Westbury, New York 11590 - United States
Status: RECRUITING
Clinical Research Site
Westmead, New South Wales 2145 - Australia
Status: RECRUITING
Clinical Research Site
Concepcion., Biobio 4070196 - Chile
Status: RECRUITING
Clinical Research Site
La Serena., Coquimbo 1720430 - Chile
Status: RECRUITING
Clinical Research Site
Santiago, Region M. De Santiago 7500921 - Chile
Status: RECRUITING
Clinical Research Site
Santiago, Region M. De Santiago 7580206 - Chile
Status: RECRUITING
Clinical Research Site
Santiago, Region M. De Santiago 8420383 - Chile
Status: RECRUITING
Clinical Research Site
Essen, Nordrhein-Westfalen 45147 - Germany
Status: RECRUITING
Clinical Research Site
Seoul, 03080 - Korea, Republic of
Status: RECRUITING
Clinical Research Site
Ciudad de México, Distrito Federal 03100 - Mexico
Status: RECRUITING
And 16 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE2 clinical trial for Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships